Creatine (Cr) supplementation has drawn much attention from researchers owing to its widespread efficacy in sports, and more recently, in therapeutic fields. However, the underlying molecular mechanisms remain elusive. Here, we performed nuclear magnetic resonance-based metabolomic analysis to address the metabolic profile of aqueous extracts from the mouse myoblast cell line C2C12 exposed to 2 mM Cr for 24 h (the Cr-treated group). Results showed that Cr supplementation facilitated the proliferation of C2C12 myoblasts. Both pattern recognition and hierarchical cluster analyses demonstrated that the metabolic profiles of the Cr-treated and control groups were distinctly different. We identified 13 characteristic metabolites significantly responsible for the discrimination of metabolic profiles between the two groups, through orthogonal projection to latent structures discriminant analysis and independent samples t-test. We further verified the discrimination performances of these metabolites by conducting univariate receiver operating characteristic curve analysis. Compared with the control group, the Cr-treated group exhibited increased levels of Cr, phosphocreatine (PCr), glutathione (GSH), and glucose, but decreased levels of leucine, valine, isoleucine, phenylalanine, methionine, choline, O-phosphocholine, sn-glycero-3-phosphocholine, and glycerol. Our results demonstrated that Cr supplementation upregulated PCr and glucose, promoted trichloroacetic acid cycle anaplerotic flux and GSH-mediated antioxidant capacity, and stabilized lipid membranes through suppressing glycerophospholipid metabolism. Our work provides new clues to the molecular mechanisms underlying the pleiotropic effects of Cr in muscle cells.
Introduction
Creatine (α-methylguanidine-acetic acid, Cr) is one of the most widely used nutritional aids in sports for its significant roles in enhancing exercise tolerance, and muscle strength and size [1, 2] . Approximately, 95% of Cr is stored in skeletal muscle, and two-thirds of intracellular Cr is converted into its phosphorylated form phosphocreatine (PCr) by Cr kinase (CK) [3] . The Cr/PCr/CK system is vital in the maintenance and management of intracellular ATP storage, especially in organs and tissues with high energy demand, such as skeletal muscle, brain, and heart [4] [5] [6] . Among the three ATP-producing systems (i.e. the Cr/PCr/CK system, anaerobic glycolysis, and aerobic oxidation), the Cr/PCr/CK system is the most rapid one for generating ATP. However, PCr content in muscle is rather limited, which reduces the capability of muscle contraction in intense levels. Therefore, Cr has long been used as an ergogenic compound. Beyond the paramount effect in energetics, in the past two decades, Cr has attracted more and more research interests from the medical field in its pleiotropic activities. Indeed, Cr supplementation has been extended to the emerging therapeutic applications. Accumulating evidence shows its pleiotropic benefits in a broad spectrum of diseases, including some muscle disorders (i.e. sarcopenia, cachexia, Duchenne, and inflammatory myopathies), central nervous diseases (i.e. Parkinson's, Huntington's, and Alzheimer's diseases), bone diseases (i.e. osteoporosis), and metabolic disturbances (i.e. type 2 diabetes) [7] . In addition, Cr supplementation could also prevent or treat a majority of Cr deficiency syndromes (CDSs) [8] . CDSs represent a novel group of inborn errors of Cr synthesis and transport, and may account for a considerable fraction of children and adults with mental retardation of unknown cause [8, 9] .
Previous reports have demonstrated that Cr plays positive roles in the perturbation of cellular bioenergetics, antioxidation, neurotrophic effect, and pro-survival and pro-differentiation effects [10] . In detail, Cr may exert effects by several manners including: (i) increasing satellite cell number and myonuclei concentration, which leads to skeletal muscle hypertrophy [11] ; (ii) activating signaling cascades, which enhances muscle differentiation and growth, such as increasing mRNA expressions of myosin heavy chain, IGF-1, IGF-2, Myo-D, Myf-5, myogenin, and MRF-4 [10, 11] ; and (iii) exerting antioxidant activity via direct or indirect mechanisms [12] . Given the importance of Cr in muscle metabolism and its multiple health promoting benefits, mechanistically understanding the pleiotropic effects of Cr will be very helpful for further exploring Cr supplementation in the treatment of neurological and muscular diseases. However, the molecular mechanisms involved are not yet completely understood.
Comprehensive analysis of cellular metabolism provides fundamental and essential information for biological systems, allowing us to clarify the molecular events associated with nutritional supplementation. In recent years, cell metabolomics have been developed as a powerful platform for analyzing metabolic profiles of cellular metabolites, and identifying involved significant metabolic pathways. As metabolites are usually the final downstream products of gene transcription, their alterations would be amplified, and the identified significant metabolic pathways are potentially better indicators of enzyme activities [13] . Thus, quantitative metabolomic analysis will be helpful to unravel consequences and influences of nutritional interventions. So far, the studies of Cr supplementation were mostly conducted by using human trials and animal experiments, and rarely carried out in vitro by applying cell metabolomic analysis. An integration of metabolomics with proteomics has been used to demonstrate that Cr supplementation could stimulate antioxidative defense in differentiated mouse myotubes [14] . In that work, however, only Cr and malate were measured as targeted metabolites with a small sample size (three parallel samples per group). Expectedly, Cr supplementation could induce comprehensive changes of metabolites and significantly alter metabolic pathways. However, both remain to be addressed.
In the present work, we conducted proton nuclear magnetic resonance ( 1 H NMR)-based cell metabolomic analysis to explore metabolic profiles, characteristic metabolites, and significantly altered metabolic pathways associated with Cr supplementation. As previously reported, Cr supplementation could enhance skeletal muscle hypertrophy, which is one of the pleiotropic benefits [15] , and muscle hypertrophy was closely related to the number of myogenic satellite cells after the fetal stage [16] . We thus used mouse myoblast cell line C2C12 (a model of activated satellite cells) to assess the effects of Cr supplementation. We found that Cr supplementation significantly facilitated the proliferation of C2C12 myoblasts, and distinctly altered cellular metabolic profiles and metabolite levels. Cr supplement-induced metabolic alterations were mostly embodied in accumulated PCr and glucose, promoted trichloroacetic acid (TCA) cycle anaplerotic flux and GSH-mediated antioxidant capacity, and stabilized lipid membranes through suppressing glycerophospholipid metabolism. This work provides new insights into the molecular mechanisms related to Cr supplementation used for the enhancement of muscle mass and strength, and the therapy of diseases.
Materials and Methods

Cell culture
Murine skeletal muscle myoblast cell line C2C12 was purchased from the China Center for Typical Culture Collection (CCTCC; Wuhan, China). Cells were maintained in commercial culture medium Dulbecco's modified Eagle's medium (DMEM; HyClone, Logan, USA) supplemented with 10% (v/v) fetal bovine serum (Gibco, Gaithersburg, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin. Cells were cultured in a humidified incubator containing 5% (v/v) CO 2 at 37°C.
MTS cell proliferation assay
The cell proliferation rate was measured using a CellTiter 96s AQueous One Solution Cell Proliferation Assay Kit (Promega, Madison, USA) according to the recommendations of the manufacturer. Cells cultured in DMEM were seeded at a density of 3×10 3 cells per well in 96-well plates. Equivalent volumes of vehicle culture media were treated as controls. After 24 h of incubation, the culture medium was replaced by fresh medium containing various concentrations of anhydrous Cr (product number C0780; Sigma-Aldrich, St Louis, USA), and the cells were incubated for an addition 24 h (just keeping consistence with the harvest time). Then, 20 μl of MTS was added to each well containing 100 μl of culture medium, and cells were incubated in the dark at 37°C for 3 h before measuring the absorbance of formazan at a wavelength of 490 nm on a microplate reader (BioTek, Winooski, USA).
Morphologies of the C2C12 myoblasts were examined using an inverted microscope (Nikon, Tokyo, Japan) after cells were fixed with 4% paraformaldehyde. Pictures were taken at randomly selected visual points after nonadherent cells were removed.
Intracellular metabolite extraction
Before metabolite extraction, 1 × 10 6 cells were seeded in 10-cm diameter culture dishes and incubated for 24 h at 37°C with 5% CO 2. Then, the culture medium was substituted with fresh medium containing 2 mM Cr and the cells were incubated for a further 24 h. Approximately 5 × 10 6 cells in each culture dish were harvested and quenched according to a direct cell quenching method as described previously [17] . After the culture medium was removed, cells were rapidly washed thrice with ice-cold phosphate-buffered saline (PBS; pH 7.4) in order to eliminate the influence of residual medium components. Once the PBS buffer was removed by vacuum, cells were immediately quenched with 3 ml of precooled high-performance liquid chromatography (HPLC) grade methanol, and then gently scratched using a cell scraper (Costar, Washington, USA). The methanol solution containing cells was pipetted into a 15-ml polypropylene centrifuge tube for extraction. Intracellular metabolites were extracted using a dual-phase extraction procedure described by Viant [18] . A mixture of HPLC grade methanol, HPLC grade chloroform, and ultrapure water at the volume ratio of 4:4:2.85 was used to generate a two-phase extract.
Sample preparation and NMR measurements
In the present study, only the aqueous phase was lyophilized and subject to 1 H NMR-based metabolomic analysis. The lyophilized intracellular metabolite extracts were resuspended in 500 μl of D 2 O and 50 μl of sodium phosphate buffer (1.5 M K 2 HPO 4 /NaH 2 PO 4 containing 0.1% TSP and 0.2% NaN 3 , pH 7.4). D 2 O was used for fieldfrequency lock, and TSP was utilized to provide the chemical shift reference (δ 0.00). All the samples were vortexed and centrifuged at 12,000 g for 15 min at 4°C to remove precipitates. The supernatants were transferred to 5-mm NMR tubes for further measurement [19] . All 1 H NMR spectra were recorded on a Bruker Avance III 850 MHz spectrometer (Bruker Bio Spin, Rheinstetten, Germany) at 25°C using the pulse sequence NOESYPR1D [(RD)-90°-t 1 -90°-τm-90°-acq] with water suppression. The spectral width was 20 ppm with an acquisition time of 1.88 s/scan, using a 4-s relaxation recovery delay. A total of 128 transients were collected into 64 K data points for each spectrum.
NMR data preprocessing
NMR spectra were processed (phase correction, baseline correction) and referenced to the methyl group of TSP using the MestReNova software (Version 6.1; Mestrelab Research S.L., Santiago de Compostela, Spain). Then, the spectra region δ 9.4-0.7 was segmented into chemical shift regions of equal width of 0.002 ppm. The data of region δ 5.2-4.5 were set to zero to eliminate distorted baseline from imperfect water saturation. The icoshift algorithm was executed to remove misalignment of NMR signals in MatLab (Version 2011b; Math Works, Natick, USA) [20] . Integrals of the metabolite peaks were measured and normalized by the integral of the TSP peak.
Chemical shifts of 1D 1 H NMR spectra were identified, assigned and validated using Chenomx NMR Suite (Version 7.7; Chenomx Inc., Edmonton, Canada) by comparing and matching the chemical shifts for various metabolites available in the software, together with the Human Metabolome Data Base (HMDB, http://www. hmdb.ca/) and other relevant published references [21] [22] [23] .
Data analysis
Prior to statistical analysis, the normalized spectral data were imported into the SIMCA-P software (Version 12.0; Umetrics AB, Umeå, Sweden) for multivariate data analysis. Pareto scaling was used to increase the importance of low-level metabolites without significant amplification of noise [24] . Unsupervised principal component analysis (PCA) was conducted to check the grouping trend and outliers. Moreover, Hierarchical cluster analysis (HCA) was performed on the binned spectral data with the MetaboAnalyst webserver (Version 3.0, http://www.metaboanalyst.ca/). Ward's method was used with the squared Euclidean distance as a measure of similarity to evaluate metabolic profile clustering.
Furthermore, supervised partial least-squares discriminant analysis (PLS-DA) was conducted to improve the group separation [25] . a high robustness. Additionally, supervised orthogonal projection to latent structures discriminant analysis (OPLS-DA) was used to identify characteristic metabolites significantly responsible for the discrimination of the metabolic profiles between the two groups [25] . OPLS-DA is a derivative PLS-DA removing uncorrected variables within-class with the orthogonal filter [25] . Two criteria were used in the OPLS-DA model. One was the variable importance in the projection (VIP) score [26] , another was the correlation coefficient (r) of the variable relative to the predictive component (t [1] ) [27] . The critical values of correlation coefficients were determined by the degrees of freedom in the OPLS-DA model. Significant metabolites were identified with VIP ≥ 1 and |r| ≥ the critical values. Univariate data analysis was also performed on the concentrations of the identified metabolites for the two groups. Concentrations of the metabolites were calculated based on their integrals relative to that of TSP with a known concentration and the proton number ratios of the metabolites to TSP. We quantitatively compared the concentrations of the metabolites between the two groups by using an independent samples t-test with the SPSS software (Version 18.0; Chicago, USA). Data were expressed as the mean ± SD. The boxplot representation was utilized to visualize variations in the concentrations of the metabolites in the Cr-treated group relative to the control group. A critical P value of 0.05 was used to identify differential metabolites. Characteristic metabolites were determined by a combination of the significant metabolites identified from the OPLS-DA analysis and the differential metabolites identified from the t-test analysis.
In addition, to evaluate the performances of the determined characteristic metabolites for discriminating the Cr-treated group from the control group, univariate receiver operating characteristic (ROC) curve analysis was performed for each characteristic metabolite. The ROC curve analysis is extensively considered as the most objective and statistically valid method for biomarker performance evaluation. The area under the ROC curve (AUC) provides a robust measure for comparing the performance of different biomarker models. The models with 0.5 < AUC ≤ 0.7, 0.7 < AUC ≤ 0.9, and AUC > 0.9 provide low, fair, and superior performances, respectively.
Results
Determination of Cr concentration in the culture medium
To determine the optimal concentration of Cr supplemented in the culture medium, C2C12 myoblasts were treated with various concentrations of Cr (0.1-10 mM) for 24 h, and cell proliferation was assessed. As shown in Fig. 1 , the proliferations of C2C12 myoblasts treated with 0.1, 0.5, 1.0, 2.0, 5.0, and 10.0 mM Cr were significantly promoted by 1.11-, 1.11-, 1.15-, 1.21-, 1.11-, and 1.15-fold compared with that of controls, respectively. There was no significant morphological difference among the Cr-treated groups with various Cr concentrations. Cr supplementation at 2.0 mM exhibited the maximal pro-proliferative influence on C2C12 myoblasts, consistent with the relative concentration used in human experiments. According to the literature [28] , 2 mM of Cr used for incubating cells corresponds to the Cr concentration achieved in humans after a single 20 g oral 'loading' dosage. Thus, we chose 2 mM as the Cr concentration in the culture medium for subsequent cellular metabolomics experiments. No major health issues were reported in a previous study of healthy individuals administered with various doses (1-80 g/day) of Cr for up to 5 years [29] . Therefore, it could be expected that 2 mM Cr would not have significant side effects on C2C12 myoblasts at this dosage.
NMR spectra of aqueous extracts of C2C12 myoblasts H NMR spectra recorded on aqueous extracts of C2C12 myoblasts from the control and Cr-treated (2 mM) groups. Totally, 34 metabolites were identified by a combination of Chenomx NMR Suite, the HMDB, and previously published literatures [21] [22] [23] . The identified metabolites are summarized in Table 1 . These metabolites include: amino acids (leucine, isoleucine, valine, threonine, alanine, lysine, proline, glutamate, methionine, glutamine, glycine, tyrosine, histidine, and phenylalanine); Cr-relevant metabolites (Cr and PCr); glucose metabolism-related molecules (lactate, glucose, and fumarate); glycerophospholipid metabolism-related molecules [choline, O-phosphocholine (PC), sn-glycero-3-phosphocholine (GPC), and glycerol]; energy metabolism-related molecules [nicotinamide adenine dinucleotide (NAD + ) and adenine mono/di/tri phosphate (AXP)]; and other unclassified metabolites [pantothenate, acetate, pyroglutamate, glutathione (GSH), dimethylamine, methylguanidine, taurine, myo-inositol, and formate]. Visual inspection of the NMR spectra showed that culturing C2C12 myoblasts in the presence of 2 mM Cr resulted in significant accumulations of intracellular Cr and PCr (Fig. 2B) .
Multivariate data analysis for exploring cellular metabolic profiles
Due to the high information content and complexity of the NMR spectra, the spectra were further segmented and processed to conduct multivariate data analysis. At first, an unsupervised PCA model with the first two principle components (tp1 and tp2) was constructed for an overview of the data set (Fig. 3A) . No significant outlier was identified in the PCA model. The metabolic profile of the Cr-treated group was clearly separated from that of the control group along tp1. To get a better separation, a supervised PLS-DA model was built using NMR spectral data as the X-matrix and group information as the Y-matrix. The PLS-DA scores plot (Fig. 3C) illustrates an excellent distinction between the two groups. Furthermore, a random permutation test (n = 200) was conducted to evaluate the validity of the PLS-DA model. Three relevant parameters were calculated: R Additionally, to confirm the reliability of the PCA and PLS-DA models, we conducted HCA using MetaboAnalyst. The dendrogram plot (Fig. 3B) displays the clustering result. Evidently, the control group formed a separate cluster, while the Cr-treated group formed another one, which was in good agreement with the results derived from the PCA and PLS-DA models.
Expectedly, remarkable discrepancies in Cr and PCr concentrations (Fig. 2B) made much significant contributions to the distinction of metabolic profiles between the two groups. To examine the metabolic distinction contributed from other metabolites, we eliminated the NMR data relevant to Cr and PCr and conducted PLS-DA again on the edited NMR data. Even though the significant contributions from Cr and PCr were eliminated, the rebuilt PLS-DA scores plot still showed a clear-out discrimination of metabolic profiles between the two groups (Fig. 3E) . The corresponding cross-validation plot indicates good reliability of the re-established PLS-DA model (Fig. 3F) . These results demonstrated that the cellular responses to Cr treatment reflected not only the changes of cellular Cr and PCr levels, but also the overall metabolic alterations in C2C12 myoblasts.
Identification of characteristic metabolites
OPLS-DA was conducted to identify significant metabolites primarily responsible for the separation of metabolic profiles between the control group and the Cr-treated group (Fig. 4A,B) . Expectedly, the supervised OPLS-DA could retain the correlated orthogonal variable information and filter out uncorrelated orthogonal variable information to maximize metabolic distinction between the two groups. Significant metabolites were identified from the loading plot, which are color-coded according to the absolute values of the correlation coefficients (|r|) derived from the OPLS-DA model. Red, orange, and blue colors denote that the metabolites are very significant (|r| ≥ 0.708 and VIP ≥ 1), significant (0.576 ≤ |r| < 0.708 and VIP ≥ 1), and insignificant (|r| < 0.576 or VIP < 1), respectively. The upward and downward peaks correspond to the upregulated and downregulated metabolites in the Cr-treated group compared with the control group, respectively. Approximately, 14 significant metabolites were identified, including valine, leucine, isoleucine, methionine, GSH, Cr, PCr, choline, PC, GPC, glucose, threonine, glycerol, and phenylalanine.
To quantitatively assess the changes in metabolite levels, we calculated the absolute concentrations of the identified metabolites based on the integrals of the metabolites relative to the integral of TSP with a known concentration as a reference. Then, we performed a further independent samples t-test with a threshold P value of 0.05 ( Table 2) . The determined differential metabolites were almost consistent with the significant metabolites identified from the OPLS-DA model. As an exception, threonine was not identified as a statistically differential metabolite, even though it was identified as a significant metabolite. Thus, totally 13 characteristic metabolites were determined by a combination of the significant metabolites and differential metabolites. Compared with the control group, the Cr-treated group showed significantly increased levels of Cr, PCr, GSH, and glucose, and distinctly decreased levels of the other metabolites, including leucine, valine, isoleucine, phenylalanine, methionine, choline, PC, GPC, and glycerol (Fig. 4C) . Additionally, we also calculated Pearson's correlation coefficients between the Cr-relevant metabolites (Cr, PCr, and total Cr) and the other characteristic metabolites to explore their potential statistical relationships (Fig. 4D) . Interestingly, the Crrelevant metabolites exhibited positive correlations with glucose and GSH, and negative correlations with three amino acids (valine, phenylalanine, and methionine) and two intermediates of glycerophospholipid metabolism (choline and PC).
Then, the univariate ROC curve analysis was performed for each characteristic metabolite to evaluate its performance in discriminating the Cr-treated group from the control group. As expected, both ROC curves based on Cr and PCr reach the largest AUC value of 1.00 (Table 2) . Moreover, the ROC curves based on the other 11 individual characteristic metabolites also have high performances with AUC values > 0.80 ( Table 2) . These results verified the significances of the 13 characteristic metabolites identified by using a combination of multivariate OPLS-DA analysis and univariate t-test analysis.
Significantly altered metabolic pathways under Cr treatment
To visualize the Cr treatment-induced changes in the characteristic metabolite levels, we projected these metabolites onto a metabolic map based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.kegg.jp/kegg/pathway.html). As a comprehensive knowledge repository, KEGG has been extensively utilized as one of the main data resources to reconstruct metabolic networks and identify significant metabolic pathways. Figure 5 illustrates the significantly altered metabolic pathways under Cr treatment, including energy metabolism, glycerophospholipid metabolism, GSH biosynthesis, and TCA cycle anaplerotic flux. Both the changed characteristic metabolites and altered metabolic pathways provide new insights into the molecular mechanisms underlying the effects of Cr supplementation.
Discussion
Cr has been extensively recognized not only as a popular ergogenic supplement in sports, but also as a promising conjunct treatment in a broad range of diseases from a clinical perspective. However, the molecular mechanisms underlying the pleiotropic effects of Cr Figure 4 . Identification of characteristic metabolites significantly responsible for discriminating the metabolic profiles between the control and Cr-treated groups (A) OPLS-DA scores plot. (B) OPLS-DA correlation coefficient-coded loading plot identifying the metabolites significantly contributing to the discrimination of the metabolic profiles. (C) Comparison of the concentrations of characteristic metabolites between the two groups. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. the control group. (D) Heat map displays inter-metabolite correlations between Cr-relevant metabolites (Cr, PCr, and total Cr) and other characteristic metabolites. Total Cr (TCr) is the sum of Cr and PCr. Both correlation coefficients and statistical significances were calculated with the Pearson formula. Color bars represent statistical significances of the correlation coefficients: red, positive correlations; blue, negative correlations. *P < 0.05 and **P < 0.01 vs. the control group. Val, valine; Ile, leucine; Leu, isoleucine; Met, methionine; GSH, glutathione; Cr, creatine; PCr, phosphocreatine; Cho, choline; PC, O-phosphocholine; GPC, sn-glycero-3-phosphocholine; Glc, glucose; Thr, threonine; G, glycerol; Phe, phenylalanine. supplementation remain to be addressed in detail. In the present work, we carried out a cellular metabolomic study to mechanistically interpret the effects of Cr supplementation, by integrating 1 H NMR spectroscopy with multiple data analysis methods, including unsupervised PCA, supervised PLS-DA and OPLS-DA, HCA, independent samples t-test, and ROC curve analysis. We have addressed the Cr supplement-induced metabolic alterations, and identified characteristic metabolites and significantly altered metabolic pathways.
It is well known that myogenic satellite cells are the primary cellular source of muscle growth and regeneration. Satellite cell proliferation is an essential process for providing a sufficient number of muscle progenitors in muscle growth and repair, and normal functioning of satellite cells is vital to maintain skeletal muscle homeostasis [30] . Therefore, myoblast proliferation is an early and critical step during myogenesis, and the enhancement of myoblast proliferation is the fundamental condition for promoting hypertrophy. We found that Cr supplementation had a significant stimulative influence on the proliferation of C2C12 myoblasts, reflecting the growthpromoting effect of Cr.
In response to Cr supplementation, the intracellular levels of Cr, PCr, GSH, and glucose were significantly increased, while those of some metabolites were distinctly decreased, including amino acids (leucine, valine, isoleucine, phenylalanine, and methionine), and intermediates of glycerophospholipid metabolism (choline, PC, GPC, and glycerol). These altered metabolites are potentially related to several metabolic pathways including energy metabolism, glycerophospholipid metabolism, GSH biosynthesis, and TCA cycle anaplerotic flux.
It has been demonstrated that over 90% of cellular Cr uptake is facilitated via a specific Na + and Cl -dependent Cr transporter against a concentration gradient [31] . Our observation that Cr supplementation enhanced the intracellular Cr level in C2C12 myoblasts, confirmed the expected increased uptake of Cr by the cells. Similar findings have been substantially documented in cells [28] , rats [32] , and humans [33] . Furthermore, Cr supplementation would stimulate the Cr-PCr system. Upon entering the cells, a large proportion of Cr would be converted to PCr via the Cr kinase reaction (Cr + ATP ↔ PCr + ADP + H + ) [3] . Our data indicated that PCr was greatly upregulated in the Cr-treated group compared with that in the control group, indicating massive consumption of ATP and high production of ADP. As reported previously, the increases in the ADP/ATP ratio and/or the AMP/ATP ratio would activate AMPactivated protein kinase (AMPK), which serves as an important energy sensor to preserve ATP levels [34] . Previous reports have demonstrated that AMPK is activated after Cr supplementation in skeletal muscle cells [28] , and AMPK activation usually plays a crucial role in promoting glucose intake in skeletal muscle [35, 36] . The findings of our study well support these previous results. We found that Cr supplementation induced an accumulation of glucose in C2C12 myoblasts cultured in a high-glucose medium DMEM, and the glucose level was positively correlated with the Cr level. Additionally, we also observed declined levels of four amino acids (valine, isoleucine, leucine, and phenylalanine) in the metabolic response to Cr supplementation. All of these amino acids can be utilized as alternative sources of TCA cycle anaplerosis [37] . Since AMPK activation results in the reinforcement of oxidative phosphorylation [38, 39] , these metabolic alterations might be attributed to the fact that more active TCA cycle anaplerotic flux occurs with the increase in the intracellular Cr level.
Oxidative phosphorylation is the main source of cellular reactive oxygen species (ROS) [40] . Hence, enhanced oxidative phosphorylation would augment the generation of ROS, which could account for the significant rise in the GSH level in the Cr-treated group and the positive correlation between the levels of GSH and Cr. As the most abundant nonprotein thiol in the antioxidant defense system, GSH plays a vital role in protecting cells against oxidative stress either by directly scavenging ROS or by indirectly serving as a cofactor in specific antioxidative enzymes. Our finding that Cr supplementation induces upregulated GSH in C2C12 myoblasts is consistent with a previous study in exercising rats which showed that Cr supplementation attenuated the decrease in the muscle GSH level, and prevented the drop in the GSH/GSSG ratio in rats undergoing an acute exercise [41] . In fact, there have been plenty of evidence showing that Cr supplementation could exert protective effects against an array of oxidative agents in acellular systems [42] , various types of the cells such as C2C12 myoblasts [12] , rats [43] , and Absolute concentrations of the characteristic metabolites were quantified based on the integrals of the metabolites relative to the integral of TSP with a known concentration as a reference.
b P values were calculated using independent samples t-test, and significant changes are assigned: *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group. c Metabolites with '↑/↓' mean increased/decreased concentrations in the Cr-treated group compared with the control group.
Drosophila melanogaster [44] . Cr supplementation results in an improved ability of maintaining the defense system against oxidative stress, and the GSH level potentially works as an indicator of such ability.
Although the antioxidant capacity of Cr has been verified in many studies, the underlying mechanism is still being disputed [12] . The enhanced level of GSH detected in this work suggest that GSH biosynthesis may be one of key metabolic pathways related to activation of the antioxidant system upon Cr supplementation. This is supported by the reduced level of methionine which is a necessary cysteine precursor for GSH synthesis [45] . Furthermore, it was reported that Cr supplementation could activate the thiol redox system, which was involved in the GSH pathway [14] . These results suggested that Cr supplementation exerted a significant influence on the biosynthesis of GSH. The detail molecular mechanisms will be further explored in future studies.
As mentioned above, Cr supplementation could stimulate the Cr/ PCr/CK system and enhance antioxidant capacity. Even though less documented, Cr supplementation is also expected to have a crucial effect on the stabilization of lipid membranes. Previous reports showed that exogenous PCr could alleviate muscle damage in cardiac tissue by stabilizing membrane phospholipid bilayer, reducing membrane fluidity, and turning membrane into a more ordered state [11] . A recent work reported that PCr could interact with phospholipids to facilitate membrane stabilization and protect against membrane permeabilisation [46] . Consistent with previous studies, our work revealed the declined levels of four intermediates of glycerophospholipid metabolism (choline, PC, GPC, and glycerol), which were potentially associated with the stabilization of phospholipid membranes as well. As well known, phosphatidylcholine makes up approximately one-half of membrane phospholipids. Both choline and PC are necessary precursors of phosphatidylcholine, while GPC and glycerol are breakdown products of phosphatidylcholine. The variations in these metabolite levels were potentially related to either synthesis or degradation of membrane phospholipids in glycerophospholipid metabolism. Evidence has accrued that the increase in PC and GPC levels indicates the activation of choline kinase and promotion of membrane breakdown by phospholipases [47] . Accordingly, the significant decreases in these metabolite levels potentially facilitate the attenuation of membrane breakdown. These results suggested that Cr supplementation might enhance the stability of lipid membranes through suppressing glycerophospholipid metabolism. It is noteworthy that so far, little information is available on the relationship between Cr supplementation and glycerophospholipid metabolism. Further studies are required in the future.
In summary, this work has evaluated the metabolic responses of the mouse myoblast cell line C2C12 to the incubation with 2 mM Cr. We found that Cr supplementation facilitated the proliferation of C2C12 myoblasts, altered the cellular metabolic profile, upregulated PCr and glucose, promoted TCA cycle anaplerotic flux and GSH-mediated antioxidant capacity, and stabilized lipid membranes via the suppression of glycerophospholipid metabolism. These results shed new light on the mechanistic understanding of the pleiotropic effects of Cr in muscle cells, and may be helpful for further exploring Cr supplementation in sports and therapeutic fields.
